Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A

Kouris, Anargyros; Agiasofitou, Euthymia; Gregoriou, Stamatis; Sofouri, Evangelia; Panagopoulos, Gregorios; Kontochristopoulos, Georgios

doi:10.1111/ijd.12625

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High doses of BoNT-A injected intradermally in one session increase also the risk of systemic neurological side effects. Kouris et al reported the case of a young woman treated with 400 BoNT-A totally in one session for palmoplantar hyperhidrosis who experienced three days after the injection dizziness, headache, nausea, muscular weakness, muscular pain, inability to maintain support, difficulty in opening her eyelids, weakness of eye focus, and somnolence [45]. The symptoms presented progressive improvement and receded completely after six weeks.…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

“…Botulinum toxin proved to be a more effective treatment modality for palmar hyperhidrosis than iontophoresis with aluminum chloride (80% vs 47%, p = 0.007) [ 33 ]. The persistence of improvement in HRQL for botulinum toxin therapy was on average only 4 months with frequent serious side-effects such as disturbed neuromuscular transmission and generalized neurological symptoms [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Bilateral one-stage single-port sympathicotomy in primary focal hyperhidrosis, a prospective cohort study: treat earlier?

Kuijpers

Peeters

Harms

et al. 2021

J Cardiothorac Surg

View full text Add to dashboard Cite

Background Primary Focal Hyperhidrosis (PFH) has a detrimental effect on Quality of Life. Repetitive, non-curative symptomatic strategies dominate current treatment of PFH, in spite of the availability of an effective and permanent curative treatment like Endoscopic Thoracic Sympathectomy (ETS). Current surgical optimization may allow for a re-established position of sympathetic modulation in this treatment algorithm. We sought to evaluate the safety, effectiveness, and long-term results of a Bilateral One-stage Single-port Sympathicotomy (BOSS) procedure in PFH patients and to identify subgroups benefitting most. Methods Prospective analysis of 163 patients, 35 (21.5%) underwent Rib-3 (R3) BOSS for palmar PFH, 58 (35.6%) R3-R5 BOSS for axillary PFH and 70 (42.9%) R3-R5 BOSS for combined palmar/axillary PFH. Effectiveness was measured using Skindex-29 and the Hyperhidrosis Disease Severity Scale (HDSS). Results Overall Skindex-29-rating (46.5 ± 14.8 preoperatively vs 20.1 ± 20.6 postoperatively, p < 0.001), and HDSS score (3.71 ± 0.45 preoperatively vs 1.82 ± 0.86 postoperatively, p < 0.001) indicated a significant improvement in health-related quality of life after BOSS. R3 BOSS was superior to R3-R5 BOSS in terms of HDSS score (1.49 vs 1.91 respectively, p = 0.004) and in terms of severe compensatory hyperhidrosis, a frequently reported side-effect (17.1% vs 32.8% respectively, p < 0.001). No major complications occurred. Conclusions BOSS is safe, effective, and offers a long-term curative solution in the treatment of PFH. Especially in the palmar PFH subgroup, R3 BOSS treatment results compare favorably to the treatment results of non-curative alternatives published in the current literature. Therefore, R3 BOSS should be offered to all patients with severe PFH, reporting insufficient benefit of treatment options such as oral and/or local agents.

show abstract

Botulinum toxin A

2015

Reactions Weekly

View full text Add to dashboard Cite

Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A

Cited by 5 publications

References 9 publications

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Bilateral one-stage single-port sympathicotomy in primary focal hyperhidrosis, a prospective cohort study: treat earlier?

Botulinum toxin A

Contact Info

Product

Resources

About